• Sino Biopharmaceutical presented Phase III results for breast cancer drug TQB2102 at ESMO in Madrid on October 23, 2026.
• The HER2 bispecific antibody-drug conjugate delayed disease progression versus chemotherapy in patients with HER2-low recurrent or metastatic breast cancer.
• TQB2102 improved tumor response, with overall survival showing a favorable trend.
• Treatment-related lung inflammation was uncommon, with no related deaths; treatment discontinuations due to adverse events were comparable to chemotherapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief on October 23, 2026, and is solely responsible for the information contained therein.